stock-mb-logo-androidstock-mb-logo-ios
Stock Screener App
Free - Play StoreApp Store
InstallInstall
logo
Protalix BioTherapeutics Inc.PLX
$3.040.49%-0.015

Protalix BioTherapeutics Inc. (PLX)

Protalix BioTherapeutics Inc. stock is traded at $3.04, with a volume of 964,003. It is down -0.49% in the last 24 hours and up +15.84% over the past month. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
Previous Close:
$3.05
Open:
$3.00
24h Volume:
964,003
Relative Volume:
0.68
Market Cap:
$255.91M
Revenue:
$52.74M
Net Income/Loss:
-$6.60M
P/E Ratio:
-
EPS:
-$0.0845
Net Cash Flow:
-$13.63M
1W Performance:
+18.09%
1M Performance:
+15.84%
6M Performance:
+53.28%
1Y Performance:
+63.17%
1-Day Range:
$2.95$3.07
1-Week Range:
$2.45$3.14
52-Week Range:
$1.65$3.19

Protalix BioTherapeutics Inc. Stock (PLX) Company Profile

Name
Protalix BioTherapeutics Inc.
Phone
972 4 988 9488
Address
2 Snunit Street, Science Park PO Box 455, Karmiel, USA
Employee
226
Next Earnings Date
-
Latest SEC Filings
SEC
PLX's Discussions on X
X

 

Market Cap

 

Revenue

 

Net Income

 

Cash Flow

 

EPS

 

Protalix BioTherapeutics Inc. Stock (PLX) Financials Data

Similar to PLX